Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic hematopoietic stem cell transplantation (Zhejiang University)
- Development stage
- Unknown
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a cellular therapy used to treat high-risk hematologic malignancies. This specific protocol, developed by He Huang at Zhejiang University and evaluated in the MIGHT trial, utilizes HLA-mismatched unrelated donors for patients who lack suitable matched donors. The procedure involves a conditioning regimen—including myeloablative or reduced-intensity doses of busulfan, fludarabine, cyclophosphamide, and semustine—to eradicate the patient's underlying disease and suppress the immune system to allow for donor cell engraftment. The therapeutic effect is derived from the reconstitution of a healthy hematopoietic system and the 'graft-versus-leukemia' (GVL) effect, where donor-derived immune cells recognize and eliminate residual malignant cells.
- Other names
- HLA-mismatched unrelated allogeneic hematopoietic stem cell transplantationallo-HSCTUMRD-HSCT
Beyond the preview
Go deeper on allogeneic hematopoietic stem cell transplantation (Zhejiang University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic hematopoietic stem cell transplantation (Zhejiang University).